Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · November 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07863167). This is a study registration, not published results. Lead sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 660 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer. Interventions: DRUG: adebrelimab + SHR-A2009; DRUG: paclitaxel or pemetrexed combined with carboplatin +adebrelimab; DRUG: adebrelimab + SHR-A2009; DRUG: adebrelimab + SHR-A2009; DRUG: adebrelimab; DRUG: adebeliizumab + SHR-A2009; DRUG: adebeliizumab + SHR-A2009; DRUG: adebeliizumab + platinum-containing double chemotherapy; DRUG: almonertinib combined with SHR-A2009; DRUG: almonertinib combined with SHR-A2009; DRUG: almonertinib; DRUG: SHR-A2009 combined with almonertinib; DRUG: almonertinib monotherapy. Primary outcome measures: Part A1 : pCR rate; , about 24 months; Part A2 : 2-year DFS rate; , about 24 months; Part A3 : pCR rate and 18-month EFS rate; , about 18 months; Part B1 : 2-year DFS rate. , about 24 months; Part B2 : MPR rate. , about 24 months. Brief summary: The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.